ASCO 2024主要亮点

INFOGRAPHIC ASCO 2024Key Highlights Key Findings This summary examines the clinical trial environment for industry-sponsored trials with data showcased at ASCO 2024 to identifythe types of products being developed, types of cancer being studied, at what stage of development, in which regions, and forwhich group of patients.A significant number of innovative therapies are being researched; the immuno-oncology mechanism of action remains at theforefront of drug development, with PD-1/L1 inhibitors the top choice in this field. Most of the trials featured at ASCO 2024 focusedon immuno-oncology drugs . Trials bySponsor Trial Counts per Cancer Type and Phase Non-small cell lung cancer is the most researched cancer type, followed by breast and colorectal cancers. Furthermore, most ofthe industry-sponsored trials presented at ASCO 2024 were in Phase II with 46% phase II trials having completed trial status. Geographic Distribution Around46%of the industry-sponsored trials presented at ASCO 2024 were conducted byTop 20*pharma companies.Merck & Co. dominated the space, followed by Astra Zeneca, Bristol Myers Squib, and Roche.The US holds the leading position as the location where most trials are conducted, followed by China and Spain.Over64%of industry-sponsored trials presented at ASCO 2024 had a trial location in the US. Trials Based on Patient Population Many trials focused on enrolling patients based on genetic mutations or alterations. A significant portion of these trialswere either first in human or pivotal clinical trials aimed at gaining initial market approval through regulatory submission.